Articles related to CHECKPOINT INHIBITORS

Explore the findings of the A041702 study, presented at the ASCO annual meeting, which investigated the efficacy of two treatment regimens for older patients with CLL. The results, significantly influenced by COVID-19, call for further investigation and long-term follow-up to determine the potential benefits and risks.

The landscape of small cell lung cancer treatment is undergoing significant transformation with the advent of immune checkpoint inhibitors. This shift not only provides new therapeutic options but emphasizes the importance of a comprehensive team approach, including early detection strategies, and holds the promise for enhanced patient prognosis.

Second-generation androgen receptor pathway inhibitors (ARPIs) have proven to be essential in managing nonmetastatic castration-resistant prostate cancer (nmCRPC). These treatments provide hope in delaying metastasis and improving overall survival, significantly altering the disease’s prognosis.

This study demonstrates how pharmacists can improve patient safety and dramatically save costs in the management of chronic myeloid leukemia by highlighting the possibility of pharmacist-led TKI cessation programs.

A phase II trial showed a significant progression-free survival benefit when patients with HR+/HER2- metastatic breast cancer switched endocrine therapy and received ribociclib, indicating the potential of this treatment strategy for those who progress on endocrine therapy and palbociclib. Learn more about the findings and implications for clinical practice.

This article reviews the novel CXCR4 inhibitor motixafortide and its use in hematopoietic stem-cell mobilization. We present a history of stem-cell mobilization and update of recent innovations in novel mobilization strategies. Hematopoietic stem-cell mobilization is a crucial step in autologous stem-cell transplantation. Motixafortide is a novel CXCR4 inhibitor that has been shown in preclinical and clinical trials to mobilize hematopoietic stem cells (HSCs) for transplantation. The drug has extended in vivo activity (>48 h) and high affinity (Ki, 0.32 nM). In a phase 1, two-part study, motixafortide administered to healthy subjects was safe, well tolerated, and led to a rapid and robust increase in the number of circulating HSCs. Motixafortide has been evaluated in a randomized phase 3 trial for autologous transplantation in multiple myeloma. The study showed that the combination of motixafortide and granulocyte colony-stimulating factor (G-CSF) was superior to G-CSF alone in terms of the number of CD34+ cells collected and the time to engraftment. The drug has also been evaluated in combination with plerixafor, another CXCR4 inhibitor, in a phase 1/2 study for autologous transplantation in multiple myeloma. The study showed that the combination of motixafortide and plerixafor was safe and effective in mobilizing HSCs. Motixafortide has […]